MannKind Corporation (NASDAQ:MNKD) VP David Thomson unloaded 133,000 shares of MannKind stock on the open market in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $9.95, for a total value of $1,323,350.00. Following the transaction, the vice president now directly owns 102,286 shares of the company’s stock, valued at approximately $1,017,746. MannKind Corporation (NASDAQ:MNKD) weekly performance is 17.43%. On last trading day company shares ended up $10.04. Analysts mean target price for the company is $8.58. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 48.43%.
Gilead Sciences Inc (NASDAQ:GILD) CFO Robin L. Washington sold 6,426 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $82.52, for a total transaction of $530,273.52. Gilead Sciences, Inc. (NASDAQ:GILD) shares fell -0.26% in last trading session and ended the day on $82.80. Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is 3.60 %.
InterMune Inc (NASDAQ:ITMN) CEO Daniel G. Welch unloaded 3,914 shares of InterMune stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $39.19, for a total value of $153,389.66. Following the sale, the chief executive officer now directly owns 94,202 shares of the company’s stock, valued at approximately $3,691,776. InterMune Inc (NASDAQ:ITMN) shares moved up 2.28% in last trading session and was closed at $40.87, while trading in range of $39.54 – $41.24. InterMune Inc (NASDAQ:ITMN) year to date (YTD) performance is 177.46%.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 2,000 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $61.20, for a total transaction of $122,400.00. Following the completion of the transaction, the chief executive officer now directly owns 229,157 shares in the company, valued at approximately $14,024,408. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) ended the last trading day at $63.33. Company weekly volatility is calculated as 3.93% and price to cash ratio as 10.41. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) showed a positive weekly performance of 10.14%.
Ophthotech Corp (NASDAQ:OPHT) major shareholder Svlsf Iv, Llc sold 1,966,935 shares of the company’s stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $42.54, for a total value of $83,673,414.90. Following the completion of the transaction, the insider now directly owns 84,325 shares in the company, valued at approximately $3,587,186. Ophthotech Corp (NASDAQ:OPHT) weekly performance is 10.02%. On last trading day company shares ended up $45.11. Analysts mean target price for the company is $63.25. Ophthotech Corp (NASDAQ:OPHT) distance from 50-day simple moving average (SMA50) is 32.17%.